FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:727-730 February 12, 2004 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bryant, J. Related Article by Burstein, H. J. Related Article by Goss, P. E. PubMed Citation

To the Editor: Goss et al., who conducted a trial of letrozole in postmenopausal women after five years of tamoxifen therapy for breast cancer (Nov. 6 issue),¹ present their results in a manner that could influence treatment decisions more strongly than is merited by the data provided. The focus on estimates of disease-free survival four years after tamoxifen therapy, when less than 1 percent of the patients had been followed at least four years, is potentially misleading. The preliminary survival data do not show a treatment difference (95 percent confidence interval, 0.48 to 1.21). It is inappropriate that the discussion . . . [Full Text of this Article]

This article has been cited by other articles:

• Ng, R., Pond, G. R., Tang, P. A., MacIntosh, P. W., Siu, L. L., Chen, E. X. (2008). Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006. Ann Oncol 19: 481-486 [Abstract] [Full Text]  
• Mann, B. S., Johnson, J. R., Kelly, R., Sridhara, R., Williams, G., Pazdur, R. (2005). Letrozole in the Extended Adjuvant Treatment of Postmenopausal Women with History of Early-Stage Breast Cancer Who Have Completed 5 Years of Adjuvant Tamoxifen. Clin. Cancer Res. 11: 5671-5677 [Abstract] [Full Text]